DreamCIS Inc
KOSDAQ:223250
DreamCIS Inc
Research & Development
DreamCIS Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
DreamCIS Inc
KOSDAQ:223250
|
Research & Development
-₩919.9m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Research & Development
-₩173.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-176%
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Research & Development
-₩10.7B
|
CAGR 3-Years
-158%
|
CAGR 5-Years
-74%
|
CAGR 10-Years
N/A
|
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Research & Development
-₩15.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-24%
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Research & Development
-₩20.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Research & Development
-₩171.1B
|
CAGR 3-Years
-72%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-36%
|
|
DreamCIS Inc
Glance View
DreamCIS, Inc. operates as clinical trial agency which engages in the provision of clinical online information and consultation services. The company is headquartered in Seoul, Seoul. The company went IPO on 2020-05-22. The firm mainly provides services include regulatory post-marketing surveillance (rPMS), clinical trial, non-interventional study (NIS) and others. The firm provides its services within domestic market and to overseas markets.
See Also
What is DreamCIS Inc's Research & Development?
Research & Development
-919.9m
KRW
Based on the financial report for Dec 31, 2024, DreamCIS Inc's Research & Development amounts to -919.9m KRW.
What is DreamCIS Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-46%
Over the last year, the Research & Development growth was -25%. The average annual Research & Development growth rates for DreamCIS Inc have been -49% over the past three years , -46% over the past five years .
